Secukinumab treatment of hidradenitis suppurativa: questions remain

Lancet. 2024 Feb 17;403(10427):617. doi: 10.1016/S0140-6736(23)01617-3.

Authors

Michioki Endo¹, Masahiro Kami²

Affiliations

¹ Mitoyo General Hospital, Kagawa 7691695, Japan. Electronic address: michiokiendo.med@gmail.com.
² Medical Governance Research Institute, Tokyo, Japan.

PMID: 38368011
DOI: 10.1016/S0140-6736(23)01617-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Hidradenitis Suppurativa* / drug therapy
Humans
Severity of Illness Index

Substances

secukinumab
Antibodies, Monoclonal, Humanized